One of the world’s most unique and important texts—the General e grand estoria will soon be translated, analyzed and made widely available, thanks to a global endeavour led by a UBC Okanagan researcher.

Dr. Francisco Peña, Professor in the Faculty of Creative and Critical Studies, is leading a team of international scholars in the collaborative effort to translate and digitally preserve the General estoria (GE)—the largest universal history written in Medieval Europe.

Findings from the Melanoma Group at the Spanish National Cancer Research Centre (CNIO) led to the creation of the Spanish company Highlight Therapeutics, which has developed the compound BO-112.

BO-112 is the first cancer drug candidate based on CNIO research to reach studies in patients, where it has shown activity against different cancer types.

Highlight Therapeutics and CNIO are collaborating to proof BO-112 effectiveness against the most common form of skin cancer, which is linked to sun exposure and is on the rise.

It is a private-public collaboration project, which has received almost three million in funding from the Spanish Ministry of for Science, Innovation and Universities.

CNIO researcher Marisol Soengas says, “it’s a thrill for us to contribute to the testing of BO-112 in basal cell carcinoma, one of the most common types of cancer, is exciting.”